Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-08-26 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2019年半年度报告提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (392 characters) stating that the company's 2019 semi-annual report and its summary have been disclosed on the official information disclosure website. It urges investors to review the report. There is no actual financial data or detailed report content included, only a notification of the report's publication. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA), not the report itself.
2019-08-26 Chinese
独立董事关于第四届董事会第二十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's fourth board meeting, specifically addressing the 2019 semi-annual report and related issues such as external guarantees, use of raised funds, change of accounting policies, and real estate reclassification. It references the 2019 half-year period and discusses compliance with regulatory requirements and internal procedures. The document does not contain full financial statements or comprehensive financial data but rather an independent opinion on specific governance and financial matters related to the interim report. Given the nature of the document as an independent directors' opinion on the interim report and related governance issues, it fits best under the category of Board/Management Information (MANG), which includes announcements related to board matters and management opinions. The document length is short (2092 characters), and it is not a full interim report or financial statement, nor is it a simple announcement of a report publication. Therefore, the classification is MANG with high confidence.
2019-08-26 Chinese
第四届董事会第二十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of the 2019 semi-annual report and related matters such as the use of raised funds, reclassification of real estate, and accounting policy changes. It references the 2019 semi-annual report but does not contain the report itself or detailed financial statements. The document is relatively short (1892 characters) and serves as an official announcement of board meeting decisions rather than the full interim report. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2019-08-26 Chinese
2019年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "康芝药业股份有限公司 2019 年半年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2019 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion, and analysis for the half-year period ending 2019. The content includes financial metrics, business segments, operational details, and risk disclosures typical of an interim or quarterly report. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-26 Chinese
第四届监事会第二十五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. regarding the approval of the company's 2019 semi-annual report and related matters such as the use of raised funds, change of accounting policies, and reclassification of real estate assets. It includes voting results and assurances of compliance with laws and regulations. The document is short (1462 characters) and primarily announces the decisions made by the Supervisory Board rather than containing the full semi-annual report or detailed financial statements. Therefore, it is not the interim/quarterly report itself but an announcement of resolutions related to it. This fits best with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-08-26 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kangzhi Pharmaceutical Co., Ltd. regarding a change in accounting policies. It details the adoption of new financial instrument accounting standards issued by the Ministry of Finance of China, effective from January 1, 2019, and changes in financial statement formats starting from the 2019 interim report. The document includes explanations of the policy changes, their impact on financial statements, and opinions from independent directors and the supervisory board. The document length is 3456 characters, which is relatively short and primarily serves as an announcement of the accounting policy change rather than a full financial report. It does not contain actual financial statements or substantive financial data but rather explains the policy change and its implications. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for announcements and compliance-related disclosures that do not fit other specific categories.
2019-08-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.